Q1 2024 EPS Estimates for Vigil Neuroscience, Inc. (NASDAQ:VIGL) Lowered by Analyst

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Equities research analysts at Wedbush reduced their Q1 2024 earnings estimates for shares of Vigil Neuroscience in a research note issued to investors on Tuesday, March 26th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.57) per share for the quarter, down from their previous forecast of ($0.48). The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.56) per share. Wedbush also issued estimates for Vigil Neuroscience’s Q2 2024 earnings at ($0.61) EPS and FY2024 earnings at ($2.33) EPS.

VIGL has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $24.00 target price on shares of Vigil Neuroscience in a research note on Wednesday. Morgan Stanley cut shares of Vigil Neuroscience from an “equal weight” rating to an “underweight” rating and reduced their price objective for the stock from $13.00 to $4.00 in a research note on Tuesday, December 19th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.40.

Vigil Neuroscience Stock Up 6.6 %

Vigil Neuroscience stock opened at $3.41 on Thursday. The firm has a fifty day simple moving average of $3.06 and a two-hundred day simple moving average of $4.32. Vigil Neuroscience has a twelve month low of $2.53 and a twelve month high of $11.11. The company has a market capitalization of $122.35 million, a PE ratio of -1.60 and a beta of 1.80.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. PEAK6 Investments LLC boosted its holdings in shares of Vigil Neuroscience by 66.0% in the 3rd quarter. PEAK6 Investments LLC now owns 23,796 shares of the company’s stock valued at $128,000 after acquiring an additional 9,459 shares during the last quarter. Bank of America Corp DE acquired a new stake in Vigil Neuroscience during the fourth quarter worth about $124,000. JPMorgan Chase & Co. purchased a new position in Vigil Neuroscience during the second quarter worth about $120,000. Morgan Stanley boosted its stake in Vigil Neuroscience by 6,893.8% during the fourth quarter. Morgan Stanley now owns 9,092 shares of the company’s stock worth $114,000 after buying an additional 8,962 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Vigil Neuroscience by 87.1% in the second quarter. Renaissance Technologies LLC now owns 37,488 shares of the company’s stock valued at $97,000 after purchasing an additional 17,447 shares during the period. Institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.